Bu Shanshan, Yuan Fangfang, Wei Xudong, Yin Qingsong, Li Yufu, Mi Ruihua, Yang Haiping, Li Hongyi, Ge Shoubei, Liu Yanyan, Song Yongping
Department of Hematology, Tumor Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China.
Department of Hematology, First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China.
Exp Ther Med. 2016 Jun;11(6):2437-2445. doi: 10.3892/etm.2016.3249. Epub 2016 Apr 11.
The aim of the present study was to compare the efficacy of an L-asparaginase-based regimen and a CHOP regimen followed by radiotherapy as first-line treatments for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma (ENKTL). A total of 69 patients received the CHOP regimen as the first-line treatment and 112 patients received the L-asparaginase-based regimen. All patients received radical radiotherapy following two cycles of chemotherapy. The overall response rates of the L-asparaginase-based and CHOP treatment groups were 90.18 and 72.46%, respectively (P=0.002). The one, two, and five-year overall survival (OS) rates and progression-free survival (PFS) rates of the L-asparaginase group were 96.0, 88.3, 65.1, 94.2, 79.8 and 50.0%, respectively. The one, two, and five-year OS and PFS rates of the CHOP group were 82.6, 61.9, 25.8, 63.8, 44.0 and 21.0%, respectively (P<0.001). Compared with CHOP treatment, L-asparaginase-based chemotherapy combined with radiotherapy was a safe and highly effective treatment for newly diagnosed ENKTL.
本研究的目的是比较以左旋门冬酰胺酶为基础的方案和CHOP方案联合放疗作为新诊断的鼻型结外自然杀伤细胞/T细胞淋巴瘤（ENKTL）一线治疗的疗效。共有69例患者接受CHOP方案作为一线治疗，112例患者接受以左旋门冬酰胺酶为基础的方案。所有患者在两个周期化疗后接受根治性放疗。以左旋门冬酰胺酶为基础的治疗组和CHOP治疗组的总缓解率分别为90.18%和72.46%（P=0.002）。左旋门冬酰胺酶组的1年、2年和5年总生存率（OS）及无进展生存率（PFS）分别为96.0%、88.3%、65.1%、94.2%、79.8%和50.0%。CHOP组的1年、2年和5年OS及PFS分别为82.6%、61.9%、25.8%、63.8%、44.0%和21.0%（P<0.001）。与CHOP治疗相比，以左旋门冬酰胺酶为基础的化疗联合放疗是新诊断ENKTL的一种安全且高效的治疗方法。
